 - Participants must be at high risk as defined by a history of breast cancer invasive or ductal breast carcinoma in situ DCIS and be at least 5 years out from diagnosis, or lobular carcinoma in situ LCIS, or proliferative benign breast disease such atypical ductal hyperplasia ADH, atypical lobular hyperplasia ALH or genetic test confirmation of BRCA 12 mutation carrier or have a breast cancer risk assessment 1.7 in 5 years or a lifetime risk 20 